These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30366875)

  • 1. Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.
    Milione M; Maisonneuve P; Pellegrinelli A; Spaggiari P; Centonze G; Coppa J; Delconte G; Droz Dit Busset M; Lanhazo O; Pruneri G; Mazzaferro V
    Eur J Surg Oncol; 2019 May; 45(5):755-760. PubMed ID: 30366875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review.
    Pezzilli R; Partelli S; Cannizzaro R; Pagano N; Crippa S; Pagnanelli M; Falconi M
    Adv Med Sci; 2016 Mar; 61(1):147-53. PubMed ID: 26774266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.
    Primavesi F; Klieser E; Cardini B; Marsoner K; Fröschl U; Thalhammer S; Fischer I; Hauer A; Urbas R; Kiesslich T; Neureiter D; Zitt M; Klug R; Wundsam H; Sellner F; Karner J; Függer R; Cakar-Beck F; Kornprat P; Öfner D; Stättner S;
    Eur J Surg Oncol; 2019 Feb; 45(2):198-206. PubMed ID: 30262324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics?
    Rebours V; Cordova J; Couvelard A; Fabre M; Palazzo L; Vullierme MP; Hentic O; Sauvanet A; Aubert A; Bedossa P; Ruszniewski P
    Dig Liver Dis; 2015 Nov; 47(11):973-7. PubMed ID: 26169284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors.
    Richards-Taylor S; Tilley C; Jaynes E; Hu H; Armstrong T; Pearce NW; Plant R; Cave J
    Pancreas; 2017; 46(10):1354-1358. PubMed ID: 28984786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
    Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
    Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival.
    Massironi S; Rossi RE; Zilli A; Casazza G; Ciafardini C; Conte D
    Oncotarget; 2016 Apr; 7(14):18978-83. PubMed ID: 26959887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated Ki-67 labeling index in 'synchronous liver metastases' of well differentiated enteropancreatic neuroendocrine tumor.
    Zen Y; Heaton N
    Pathol Int; 2013 Nov; 63(11):532-8. PubMed ID: 24274715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors.
    Shi C; Gonzalez RS; Zhao Z; Koyama T; Cornish TC; Hande KR; Walker R; Sandler M; Berlin J; Liu EH
    Am J Clin Pathol; 2015 Mar; 143(3):398-404. PubMed ID: 25696798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study.
    Larghi A; Capurso G; Carnuccio A; Ricci R; Alfieri S; Galasso D; Lugli F; Bianchi A; Panzuto F; De Marinis L; Falconi M; Delle Fave G; Doglietto GB; Costamagna G; Rindi G
    Gastrointest Endosc; 2012 Sep; 76(3):570-7. PubMed ID: 22898415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
    Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
    Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
    [No Abstract]   [Full Text] [Related]  

  • 14. ASO Author Reflections: Pancreatic Neuroendocrine Tumor Recurrence and Survival Predicted by Ki67.
    Nieveen van Dijkum EJM
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):531-532. PubMed ID: 30519760
    [No Abstract]   [Full Text] [Related]  

  • 15. The Ki-67 labeling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors.
    Sugimoto S; Hotta K; Shimoda T; Imai K; Yamaguchi Y; Nakajima T; Oishi T; Mori K; Takizawa K; Kakushima N; Tanaka M; Kawata N; Matsubayashi H; Ono H
    Surg Endosc; 2016 Oct; 30(10):4239-48. PubMed ID: 26718357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis, histopathologic grading and prognostic moleculer marker analysis in patients with pancreatic neuroendocrine neoplasm].
    Bao F; Chen GR; Hui P; Cai GP
    Zhonghua Bing Li Xue Za Zhi; 2013 Jun; 42(6):426-32. PubMed ID: 24060085
    [No Abstract]   [Full Text] [Related]  

  • 17. Correlation of Ki-67 indices from biopsy and resection specimens of neuroendocrine tumours.
    Barnes J; Johnson SJ; French JJ
    Ann R Coll Surg Engl; 2017 Mar; 99(3):193-197. PubMed ID: 27490982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
    Farrell JM; Pang JC; Kim GE; Tabatabai ZL
    Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine-needle aspiration biopsy of pancreatic neuroendocrine tumors: Correlation between Ki-67 index in cytological samples and clinical behavior.
    Díaz Del Arco C; Esteban López-Jamar JM; Ortega Medina L; Díaz Pérez JÁ; Fernández Aceñero MJ
    Diagn Cytopathol; 2017 Jan; 45(1):29-35. PubMed ID: 27863178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
    Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
    Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.